1. CyteVice Alvin Dabhi Aditya Sai 5/1/2013 “Discover the discovery”

2. The Opportunity Fatty liver diseases have been linked to diabetes and obesity; affect 6 million people in the US and approximately 10-20% of Americans have significant liver fat content Global drug discovery market was $41.4 billion in 2012, with high throughput screening comprising approximately 30% of the market; this equates to a $1.3 billion market segment to be tapped within the fatty liver drug market A potential drug costs between $55 million to $1.3 billion to bring to market; contracting the drug discovery phase will save time and money for companies Discovery (5 years) Preclinical (2 years) Clinical (6 years) Marketing

3. The Product CyteVice CyteVice is a diagnostic tool capable of screening for the best agents to defat candidate livers Specially coated 96 well plate assays that can be fitted for manual or automated use Prepackaged cells sustained within device to allow for more targeted testing >85% cell viability maintained Proprietary content: Patent Pending

4. Market Description Pharmaceuticals Key customers in the liver defatting market Potential Market Size: $125 million Academic Research labs Select researchers may find product desirable Potential Market Size: $50 million Potential growth opportunities available in other diseases that can be screened and treated in similar manner (obesity, Hepatitis C, etc.)

5. Competitive Edge CyteViceCompetitors (ForteBIO, EVOTec) Direct Application to Liver Disease Specifically targetedNot targeted to specific disease Usage of CellsSpecialized cells within each plate with necessary reagents None Cell ViabilityAbove AverageAverage Precision>99% reproducible resultsClosest competitor has ~85% precision Shelf Life6 months2-3 months “Viability Assurance”Included with every deviceNone

6. Business Model Offer screening devices to our customers Product Selling Points Preset cells, reagents “Viability Assurance” Negotiate volume contracts with key resource providers, such as Life Technologies® and BD Biosciences®, at lowest possible cost

7. Our Team Key Members: CEO: Carlton Jones 3 decades of experience in developing innovative instrumentation and consumables CFO: Wendy DiCicco Long history as finance chief in biotechnology and medical device startups COO: Shannon Dahl, Ph.D. Operations officer in tissue engineering company Principal Board Advisor: Dr. Francois Berthiaume, Ph.D. Well versed in liver defatting methodologies and hepatocyte models

8. Investment Request 2 infusions of $1,000,000 and $200,000 respectively $10.5 million exit value at year 6 Investments will go into: hiring of technicians and scientists: $500,000 procurement of starting materials: $150,000 capital & property expenditures: $150,000 pilot production: $150,000 marketing, press releases, webinars, conference events, sales representatives: $250,000

9. Financial Summary Projected Cost Per Device: $80 Projected Retail Price Per Device: $250 Projected Net Present Value: $2,046,000

10. Product Timeline Secure first infusion of $1,000,000 Design coating protocol & hire technicians Procurement of resources from suppliers Year 1 Construct pilot plant Finalize coating protocol & hire scientists Publicize product in research papers, webinars, etc. 2 Pilot production Secure second infusion of $200,000 Begin selling purchase orders to customers 3 Aggressive direct marketing to potential customers Research alternative cell and capacity models 4 Begin production of alternate products & expand pipeline 5

11. Summary and Q&A CyteVice CyteVice has an important role in the drug discovery market within the area of fatty liver disease No established screening tool used in testing Addresses vital need in drug discovery Specialized platform to conduct high throughput cell based assays Selling prepackaged cells along with assays Expansion to incorporate other tissue types and therapeutics Ambitious startup with experienced advisors seeking investment for a transformative product to revolutionize drug screening